Impact of Melatonin on Driving Performance

Suhner, Andrea; Schlagenhauf, Patricia; Tschopp, Alois; Hauri-Bionda, R.; Friedrich-Koch, Andrea; Steffen, Robert

doi:10.1111/j.1708-8305.1998.tb00448.x

Cited by 35 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, neurobehavioral impairments produced by daytime melatonin appeared less pronounced than those induced by a benzodiazepine (Rogers et al, 2003). These results are consistent with the Suhner's ones (Suhner et al, 1998), which showed no effect of melatonin (5 mg) on driving skill assessed by a driving computer test battery 90 min after a daytime administration. Altogether, these results suggest that PR-M administered at bedtime is devoid of deleterious effects on cognitive performances and driving abilities of elderly subjects even early after its administration.…”

Section: Discussionsupporting

confidence: 92%

“…Several studies reported alterations of alertness and performances by acute melatonin when administered during daytime (Atkinson et al, 2005;Cajochen et al, 1996;Dollins et al, 1993;Graw et al, 2001;Lieberman et al, 1984;Neville and McNaughton, 1986;Rogers et al, 1998) but not when administered during late afternoon or at bedtime in young and middle-aged (20-57 years) healthy volunteers (Paul et al, 2003;Stone et al, 2000;Suhner et al, 1998;Wynn and Arendt, 1988). Furthermore, melatonin administered nightly for 4 weeks improved certain aspects of cognition in healthy elderly subjects (Peck et al, 2004).…”

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

Otmani

Demazieres

Staner

et al. 2008

Human Psychopharmacology

116

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 91%

Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

Otmani

Demazieres

Staner

et al. 2008

Human Psychopharmacology

116

View full text Add to dashboard Cite

show abstract

“…These data mimic previous studies (Dollins et al 1993; Dollins et al 1994; Rogers et al 2003), and further emphasize the need to caution those who take melatonin in the afternoon or evening not to drive or engage in an activity that requires full alertness, even if relatively low doses are taken. Although one noteworthy study did not find an adverse effect on driving performance after ingesting 5 mg of melatonin (Suhner et al 1998), a significant increase in subjective sleepiness emerged, which led the authors to similarly conclude that caution should be used when driving after taking melatonin.…”

Section: Discussionmentioning

confidence: 99%

Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance

Crowley

Eastman

2012

Psychopharmacology

View full text Add to dashboard Cite

Rationale We test methods to advance (shift earlier) circadian rhythms without producing misalignment between rhythms and sleep. We previously tested 1) a gradually advancing sleep/dark schedule plus morning bright light and afternoon/evening melatonin; and 2) the same sleep schedule with only morning bright light. Now we report on the same sleep schedule with only afternoon/evening melatonin. Objectives To examine phase advances, sleepiness and performance in response to melatonin compared to placebo. Methods Twelve adults (5 female) aged 20–45 years (mean ± SD = 28.3 ± 7.3 years) completed this within-subjects placebo-controlled counterbalanced study. Participants slept on fixed 8-hour sleep schedules for 9 baseline days. Then, sleep/dark was advanced by 1 h/day for 3 consecutive days of treatment. Participants took 3 mg of melatonin or placebo 11 hours before baseline sleep midpoint (the optimal time to produce phase advances) on the first treatment day and 1 hour earlier each subsequent day. We measured the dim light melatonin onset (DLMO) before and after treatment. Participants rated subjective symptoms throughout the study. They completed the Psychomotor Vigilance Task (PVT) and rated sleepiness from 1 h before pill ingestion until bedtime each treatment day. Results Melatonin produced significantly larger advances (1.3 ± 0.7 h) compared to placebo (0.7 ± 0.7 h); however, in the hours between melatonin ingestion and bed, melatonin caused sleepiness and performance decrements. Conclusions Adding afternoon/evening melatonin to the gradually advancing sleep schedule increased the phase advance, but given the side effects, like sleepiness, it is better to use morning bright light and perhaps a lower dose of melatonin.

show abstract

“…Suhner et al. found that selective attention in a signal‐detection test was affected in humans and that their subjective sleepiness was increased by daytime administration of melatonin. Graw et al.…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, recent research has suggested that melatonin is a potential candidate for additive therapy of cancer, neurodegenerative, and mental disorders requiring administration during the waking period [3,[7][8][9][10]. Because melatonin is currently used during the rest phase as a hypnotic, few data address the cognitive effects of melatonin on the activity phase [9,11]. Suhner et al [9] found that selective attention in a signal-detection test was affected in humans and that their subjective sleepiness was increased by daytime administration of melatonin.…”

Section: Introductionmentioning

confidence: 99%

Effects of acute administration of melatonin on attentional, executive, and working memory processes in rats

Liet

Amenouche

Freret³

et al. 2015

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Melatonin is a potential candidate for additive therapy in cancer, neurodegenerative, and mental disorders requiring administration during the activity phase. Nevertheless, because melatonin has mostly been used as a hypnotic, less is known about its cognitive effects. In this study, we investigated the effects of acute administration of melatonin on executive, attentional, and working memory processes in rats during the activity phase. Three doses of melatonin (6, 18, or 36 mg/kg) were tested and compared to a saline control group in two behavioral tests: the Attentional Set Shifting task (for attentional and executive processes assessment) and the Spontaneous Alternation test in a Y-maze (for working memory assessment). Our results revealed that, up to 36 mg/kg, the acute administration dose of melatonin did not alter the attentional or executive processes, nor the working memory in rats. Consequently, this result may be encouraging for the use of melatonin in additive therapy during the activity phase.

show abstract

Impact of Melatonin on Driving Performance

Abstract: The overall result of the computer test battery showed no objective adverse impact of melatonin on driving performance. However, due to the increased subjective sleepiness after administration of this hormone, caution should be exercised when driving under the influence of melatonin.

Cited by 35 publications

References 28 publications

Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers

Melatonin in the afternoons of a gradually advancing sleep schedule enhances the circadian rhythm phase advance

Effects of acute administration of melatonin on attentional, executive, and working memory processes in rats

Contact Info

Product

Resources

About